Pharmacy Giants Set To Start Offering Abortion Pills In THESE States

This follows the Food and Drug Administration's (FDA) announcement in January 2023 that pharmacies could begin dispensing the abortion pill mifepristone to patients.

The two pharmacy chains have confirmed that they will stock the pills in select stores where abortion is legal, but will not permit the medication to be mailed. "We are beginning a phased rollout in select locations to allow us to ensure quality, safety and privacy for our patients, providers and team members," stated Fraser Engerman, a spokesperson for Walgreens.

The abortion pill will be available in Walgreens stores in New York, Pennsylvania, Massachusetts, California, and Illinois. CVS Pharmacy will also stock the pill in Massachusetts and Rhode Island. Both companies are keeping a close eye on states like Kansas, Montana, and Wyoming, which have abortion laws in place but are currently prohibited from enforcing them due to a court order.

 WATCH: BRITISH COLONEL RICHARD KEMP REPORTING FROM GAZA

Amy Thibault, a spokesperson for CVS, told the Times, "We continually monitor and evaluate changes in state laws and will dispense mifepristone in any state where it is or becomes legally permissible to do so."

 WATCH: NO CLUE WHY THEY ARE PROTESTING: "I WISH I WAS MORE EDUCATED"

March 03, 2024

Pharmacies can apply for certification to provide mifepristone, and women are not required to consult a doctor before obtaining the medication. However, pharmacies are obliged to inform patients about the potential risks of taking chemical abortion pills. Pro-life medical experts have cautioned that women who do not consult doctors could face serious risks of surgery and complications.

 TRUMP READY TO DEBATE BIDEN 'ANYWHERE, ANYTIME, ANYPLACE,' BUT WILL IT HAPPEN?

The FDA is currently facing a lawsuit from the American Association of Pro-Life OBGYNs and Gynecologists, the American College of Pediatricians, and the Christian Medical & Dental Association. These organizations accuse the FDA of hastily marketing the pill without taking necessary safety precautions. The Supreme Court agreed in December to hear the case, and a ruling that could limit or expand access to mifepristone is expected in the coming months.